Ir para o conteúdo principal

Bloomberg News and Videos — Page 695

Destaques de Bloomberg

Bloomberg

Extended Oil Shock Spells Higher, Sticky Inflation

The amount of inflation priced into 10-year Treasury yields is a little hard to square with what the market is saying about price rises in the near term. Either inflation is going to be high for a long time, and this is something that has changed in the past week or two, or 10-year yields have gone a little too far. Yelena Shulyatyeva, Senior US Economist at The Conference Board, discusses inflation expectations and what happens if oil prices rise higher, for longer.

Leia mais: Extended Oil Shock Spells Higher, Sticky Inflation
Bloomberg

5% is New 4% in Era of Higher Yields, Says Guneet Dhingra

A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%. Guneet Dhingra, Head of US Rates Strategy at BNP Paribas, discusses the recent yield surge and why 5% may become the new 4%.

Leia mais: 5% is New 4% in Era of Higher Yields, Says Guneet Dhingra
Bloomberg

Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers

On this episode of Stock Movers with Alexis Christoforous: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker's phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the "disappointing" trial update.

Leia mais: Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers

GARANTA JÁ SEU GRAFA EDGE

Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas